Insulin analogues with increased mitogenic potency--are they safe?
Hansen
B F
BF
Diabetes Biology, Novo Nordisk A/S, Måløv, Denmark. bfh@novonordisk.com
D000818:Animals; D015197:Carcinogenicity Tests; D002455:Cell Division / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism; D008934:Mitogens / Q000494:pharmacology*; D009152:Mutagenicity Tests; D017526:Receptor, IGF Type 1 / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000187:drug effects
D007004:Hypoglycemic Agents; D007328:Insulin; D008934:Mitogens; D017526:Receptor, IGF Type 1